Wednesday, August 12, 2026 Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX/mFFX) is the standard adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma (PDAC), offering survival benefits over gemcitabine (GEM). However, the contribution of molecular biomarkers to treatment selection remains unclear. Here, researchers characterize the molecular landscape of tumors from the PRODIGE-24/CCTG PA6 trial and assess the clinical impact of genomic alterations and molecular subtypes. Witz A, Conroy T, Lambert A, Salleron J, Diallo A, Husson M, Nicolle R, Hammel P, Biagi J, Renouf DJ, Turpin A, Richard C, Bachet J-B, Iovanna J, Dusetti N, Monard L, Mauduit M, Cros J, Harlé A. Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study (ONLINE). Journal of Clinical Oncology 2026. https://ascopubs.org/doi/abs/10.1200/JCO-25-02508
